Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Brepocitinib clears or almost clears skin in 69% of patients with cutaneous sarcoidosis in Phase 2 BEACON trial – Priovant

Written by | 17 Nov 2026 | Conference Highlights

Priovant Therapeutics has published results from the Phase 2 portion of the BEACON study of oral brepocitinib in adults with cutaneous sarcoidosis (CS) in JAMA Dermatology. Dr Misha Rosenbach of the University of Pennsylvania also presented the results in an oral session at ACR Convergence 2026 on 10 November.

CS is an inflammatory granulomatous skin disease affecting approximately 40,000 adults in the US, and it disproportionately affects Black Americans. Unlike most inflammatory skin diseases, it can rapidly cause permanent scarring and destruction of bone, cartilage and hair follicles. There are currently no FDA-approved therapies for CS.

BEACON’s Phase 2 portion was randomised, double-blind and placebo-controlled. It enrolled 31 adults, who received brepocitinib 45 mg (n=13), brepocitinib 15 mg (n=11) or placebo (n=7) once daily for 16 weeks.

Results

Both doses improved the primary endpoint, which was the change in Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score at Week 16. Scores fell by a mean of 22.3 points with 45 mg and 22.2 points with 15 mg, compared with 0.7 points with placebo (p<0.0001 for each). Improvements were visible by Week 4 and continued to grow through Week 16. On stricter responder and remission endpoints, the 45 mg dose consistently performed better, which supports a dose-dependent effect.

At Week 16, results with brepocitinib 45 mg were as follows:

  • 69.2% achieved “Clear” or “Almost Clear” skin with at least a two-category improvement, compared with 0% on placebo
  • 76.9% achieved at least a 50% reduction in CSAMI-A, compared with 0%
  • 100% achieved at least a 10-point reduction in CSAMI-A, compared with 14.3%
  • 61.5% reached a CSAMI-A score below 5, compared with 0%

Skin-related quality of life also improved. Skindex-16 scores improved by 23.5 points on brepocitinib 45 mg and worsened by 8.9 points on placebo. Every participant on 45 mg reported improvement on the Patient Global Impression of Change, compared with 29% on placebo. Post hoc analyses suggested a dose-dependent benefit in lupus pernio, a particularly difficult-to-treat form of CS. There were no serious adverse events.

“Cutaneous sarcoidosis is often on the face and severely impacts patients, and there are no approved treatments,” said Dr Rosenbach. “These published findings bring rigorous clinical evidence to a historically neglected disease and patient population.”

The Phase 3 portion, BEACON+, is enrolling approximately 140 patients at around 70 sites worldwide. Patients are randomised 3:2 to brepocitinib 45 mg once daily or placebo. The primary endpoint is the proportion of patients achieving at least a 50% reduction in CSAMI-A at Week 16. Topline data are expected in 2028.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.